Dr. Yee on Phase II ADAPT Trial Results for HER2+/HR+ Breast Cancer
Douglas Yee, MD, professor of medicine and pharmacology, Hematology, Oncology and Transplantation, Department of Medicine, medical oncologist, University of Minnesota, discusses the results of the phase II ADAPT trial, which examined T-DM1 in patients with HER2-positive, HR-positive early-stage breast cancer.
Douglas Yee, MD, professor of medicine and pharmacology, Hematology, Oncology and Transplantation, Department of Medicine, medical oncologist, University of Minnesota, discusses the results of the phase II ADAPT trial, which examined T-DM1 in patients with HER2-positive, HR-positive early-stage breast cancer.
Pathological complete response (pCR) was the trial’s primary endpoint. The pCR rate was found to be clinically meaningful in patients who received T-DM1, especially when combined with endocrine therapy. The pCR rate was significantly lower with the combination of trastuzumab plus endocrine therapy, Yee adds.
The evidence that T-DM1 is an active agent in the neoadjuvant setting was shown in this study, Yee explains. However, it is uncertain what role T-DM1 will play in the adjuvant setting. As a first-line therapy for metastatic disease, T-DM1 was previously shown to be roughly equivalent to trastuzumab, a taxane, and pertuzumab.
